Corneal Neovascularization and Allograft Survival Strategies

Corneal neovascularization, the ingrowth of blood and lymphatic vessels into the normally avascular corneal stroma, undermines the transparent optical properties of the cornea and increases the risk of graft rejection in corneal transplantation. This pathological vascularisation is driven by an imbalance between pro­angiogenic and anti­angiogenic factors, often in the context of inflammation, infection, trauma or existing ocular surface disease. Emerging strategies to manage neovascularisation focus not only on inhibiting angiogenic pathways, notably those mediated by vascular endothelial growth factor (VEGF), but also on restoring the cornea’s immune privilege through selective vessel regression, targeted immunomodulation and advanced drug‐delivery systems. By combining surgical, pharmacological and molecular approaches, researchers aim to suppress abnormal vessel growth, preserve corneal clarity and extend allograft survival in high-risk recipients.

Research from Nature Portfolio

Recent studies have demonstrated that fine needle-diathermy (FND) can selectively regress both blood and lymphatic vessels in models of suture-induced corneal neovascularization. By applying micropuncture cauterisation to pathological vessels, researchers achieved significant vessel regression within seven days and prolonged corneal allograft survival when transplants were performed into FND-treated beds. This approach leverages the destruction of newly formed vessels to re-establish corneal avascularity without compromising adjacent healthy tissue, offering a clinically translatable preconditioning method for high-risk transplantation.

Corneal Neovascularization and Allograft Survival Strategies publication trend

The graph below shows the total number of articles in corneal neovascularization and allograft survival strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Corneal neovascularization: The pathological ingrowth of blood and lymphatic vessels into the corneal stroma, compromising transparency and immune privilege.

Allograft: A tissue transplant between genetically non-identical members of the same species, subject to immune rejection without appropriate management.

Angiogenesis: The process of new blood vessel formation from pre-existing vasculature, central to wound healing and also pathological in the cornea.

Lymphangiogenesis: The formation of new lymphatic vessels, which can facilitate immune cell trafficking and promote graft rejection.

Immune privilege: A local tissue environment that limits immune responses and inflammation, critical for maintaining corneal clarity and graft acceptance.

Anti-VEGF: Therapeutic agents that inhibit vascular endothelial growth factor signalling to prevent or regress abnormal vessel formation.

References

1. Up-to-date molecular medicine strategies for management of ocular surface neovascularization. Advanced Drug Delivery Reviews (2023).
2. Combination Nanomedicine Strategy for Preventing High-Risk Corneal Transplantation Rejection. ACS Nano (2024).
3. Genome Editing VEGFA Prevents Corneal Neovascularization In Vivo. Advanced Science (2024).
4. Fine Needle-Diathermy Regresses Pathological Corneal (Lymph)Angiogenesis and Promotes High-Risk Corneal Transplant Survival. Scientific Reports (2018).